Advances in COVID-19 mRNA vaccine development

E Fang, X Liu, M Li, Z Zhang, L Song, B Zhu… - Signal transduction and …, 2022 - nature.com
To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

S Wang, B Liang, W Wang, L Li, N Feng… - Signal transduction and …, 2023 - nature.com
Human diseases, particularly infectious diseases and cancers, pose unprecedented
challenges to public health security and the global economy. The development and …

[HTML][HTML] Complete map** of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

AJ Greaney, TN Starr, P Gilchuk, SJ Zost, E Binshtein… - Cell host & …, 2021 - cell.com
Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …

Intranasal COVID-19 vaccines: From bench to bed

A Alu, L Chen, H Lei, Y Wei, X Tian, X Wei - EBioMedicine, 2022 - thelancet.com
Currently licensed COVID-19 vaccines are all designed for intramuscular (IM) immunization.
However, vaccination today failed to prevent the virus infection through the upper respiratory …

COVID-19 vaccines: Current status and implication for use in Indonesia

Y Ophinni, AS Hasibuan, A Widhani… - Acta Medica …, 2020 - actamedindones.org
Abstract The coronavirus disease 2019 (COVID-19) has inflicted catastrophic damages in
public health, economic and social stability—putting life globally on hold in 2020 and …

[HTML][HTML] Viral vectors for COVID-19 vaccine development

K Lundstrom - Viruses, 2021 - mdpi.com
Vaccine development against SARS-CoV-2 has been fierce due to the devastating COVID-
19 pandemic and has included all potential approaches for providing the global community …

[HTML][HTML] Development of nasal vaccines and the associated challenges

X Nian, J Zhang, S Huang, K Duan, X Li, X Yang - Pharmaceutics, 2022 - mdpi.com
Viruses, bacteria, fungi, and several other pathogenic microorganisms usually infect the host
via the surface cells of respiratory mucosa. Nasal vaccination could provide a strong …

Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse

Y Du, Y Xu, J Feng, L Hu, Y Zhang, B Zhang, W Guo… - Vaccine, 2021 - Elsevier
The emergence of the global Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-
CoV-2) pandemic underscores the importance of the rapid development of a non-invasive …

COVID-19 vaccines: where did we stand at the end of 2023?

K Lundstrom - Viruses, 2024 - mdpi.com
Vaccine development against SARS-CoV-2 has been highly successful in slowing down the
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …

Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa

J Tang, L Cai, C Xu, S Sun, Y Liu, J Rosenecker… - Nanomaterials, 2022 - mdpi.com
Recent advancements in the field of in vitro transcribed mRNA (IVT-mRNA) vaccination have
attracted considerable attention to such vaccination as a cutting-edge technique against …